# Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

> **NCT04447911** · PHASE4 · RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 172 (estimated)

## Conditions studied

- Hyponatremia
- SIADH
- Liver Failure
- Kidney Failure

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04447911
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-04
- **Primary completion:** 2027-01
- **Final completion:** 2027-02
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2025-11-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447911, "Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04447911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*